JP2022169504A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022169504A5 JP2022169504A5 JP2022112873A JP2022112873A JP2022169504A5 JP 2022169504 A5 JP2022169504 A5 JP 2022169504A5 JP 2022112873 A JP2022112873 A JP 2022112873A JP 2022112873 A JP2022112873 A JP 2022112873A JP 2022169504 A5 JP2022169504 A5 JP 2022169504A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322707P | 2016-04-14 | 2016-04-14 | |
| US62/322,707 | 2016-04-14 | ||
| EP17305182 | 2017-02-17 | ||
| EP17305182.2 | 2017-02-17 | ||
| JP2018550322A JP7491666B2 (ja) | 2016-04-14 | 2017-04-14 | 新規な抗ＳＩＲＰａ抗体およびそれらの治療適用 |
| PCT/EP2017/059071 WO2017178653A2 (en) | 2016-04-14 | 2017-04-14 | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550322A Division JP7491666B2 (ja) | 2016-04-14 | 2017-04-14 | 新規な抗ＳＩＲＰａ抗体およびそれらの治療適用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022169504A JP2022169504A (ja) | 2022-11-09 |
| JP2022169504A5 true JP2022169504A5 (enExample) | 2023-02-20 |
| JP7549626B2 JP7549626B2 (ja) | 2024-09-11 |
Family
ID=65529144
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550322A Active JP7491666B2 (ja) | 2016-04-14 | 2017-04-14 | 新規な抗ＳＩＲＰａ抗体およびそれらの治療適用 |
| JP2022112873A Active JP7549626B2 (ja) | 2016-04-14 | 2022-07-14 | 新規な抗ＳＩＲＰａ抗体およびそれらの治療適用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550322A Active JP7491666B2 (ja) | 2016-04-14 | 2017-04-14 | 新規な抗ＳＩＲＰａ抗体およびそれらの治療適用 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11279766B2 (enExample) |
| EP (1) | EP4438626A3 (enExample) |
| JP (2) | JP7491666B2 (enExample) |
| KR (1) | KR102355240B1 (enExample) |
| CN (1) | CN115785272A (enExample) |
| CL (1) | CL2018002898A1 (enExample) |
| DK (1) | DK3443010T3 (enExample) |
| ES (1) | ES2990971T3 (enExample) |
| FI (1) | FI3443010T3 (enExample) |
| HR (1) | HRP20241316T1 (enExample) |
| HU (1) | HUE068840T2 (enExample) |
| IL (1) | IL262251B2 (enExample) |
| LT (1) | LT3443010T (enExample) |
| MA (1) | MA44665B1 (enExample) |
| MD (1) | MD3443010T2 (enExample) |
| MX (1) | MX2018012434A (enExample) |
| PH (1) | PH12018550160B1 (enExample) |
| PL (1) | PL3443010T3 (enExample) |
| RS (1) | RS66062B1 (enExample) |
| SA (1) | SA518400237B1 (enExample) |
| SI (1) | SI3443010T1 (enExample) |
| SM (1) | SMT202400438T1 (enExample) |
| UA (1) | UA126658C2 (enExample) |
| ZA (1) | ZA201806293B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12018550160B1 (en) * | 2016-04-14 | 2024-07-03 | Ose Immunotherapeutics | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| EP3658589B1 (en) * | 2017-07-26 | 2023-09-27 | Forty Seven, Inc. | Anti-sirp-alpha antibodies and related methods |
| CN111511766B (zh) | 2017-10-13 | 2024-06-07 | Ose免疫疗法 | 修饰的抗SIRPa抗体及其应用 |
| BR112020017709A2 (pt) | 2018-03-13 | 2020-12-29 | Ose Immunotherapeutics | Anticorpo anti-sirpa humana, fragmento de ligação a antígeno do mesmo ou anticorpo modificado do mesmo, composição farmacêutica, uso de um polipeptídeo, métodos para preparar um anticorpo anti-sirpa humana v1, para aumentar a apresentação cruzada de um antígeno e para avaliar a probabilidade de eficácia de um tratamento, método in vitro ou ex vivo para avaliar a probabilidade de eficácia de um tratamento, e, combinação de compostos |
| WO2019183266A1 (en) | 2018-03-21 | 2019-09-26 | ALX Oncology Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
| SG11202102851XA (en) | 2018-09-27 | 2021-04-29 | Celgene Corp | SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF |
| PH12022550835A1 (en) | 2019-10-18 | 2023-07-03 | Forty Seven Inc | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| NZ786589A (en) | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| CN112574310B (zh) | 2020-12-11 | 2023-05-05 | 浙江博锐生物制药有限公司 | 抗SIRPα抗体及其用途 |
| KR102896511B1 (ko) * | 2022-09-07 | 2025-12-08 | 주식회사 시프트바이오 | SIRPα 변이체에 특이적으로 결합하는 항체 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| EP1244707A1 (de) | 1999-11-30 | 2002-10-02 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Antikörper gegen signal-regulator-proteine |
| US20100215640A1 (en) * | 2003-04-24 | 2010-08-26 | The University Of North Carolina At Chapel Hill | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| US8613922B2 (en) * | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
| JP3936673B2 (ja) | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP1930342B1 (en) | 2006-12-04 | 2012-01-25 | Institut Pasteur | OB-fold used as scaffold for engineering new specific binders |
| JP2011500005A (ja) | 2007-10-11 | 2011-01-06 | ユニバーシティー ヘルス ネットワーク | ヒト造血幹細胞の生着を増加させるためのＳＩＲＰα−ＣＤ４７相互作用の調節およびそのための化合物 |
| MX2010003642A (es) | 2007-10-12 | 2010-08-09 | Massachusetts Inst Technology | Nanotecnologia de vacuna. |
| PT3056515T (pt) | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| DK2429574T3 (da) | 2009-05-15 | 2015-06-22 | Univ Health Network | Sammensætninger og fremgangsmåder til behandling af hæmatologiske cancere der targeterer sirp-cd47-interaktionen |
| GB201015765D0 (en) | 2010-09-21 | 2010-10-27 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
| WO2012149416A2 (en) | 2011-04-28 | 2012-11-01 | University Of Southern California | Human myeloid derived suppressor cell cancer markers |
| MX2013014789A (es) * | 2011-06-16 | 2014-01-20 | Novartis Ag | Proteinas solubles para utilizarse como productos terapeuticos. |
| WO2013056352A1 (en) | 2011-10-19 | 2013-04-25 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| EP3766511A1 (en) | 2012-01-17 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | High affinity sirp-alpha reagents |
| SG10201706383XA (en) | 2013-02-06 | 2017-09-28 | Inhibrx Lp | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| WO2015138600A2 (en) * | 2014-03-11 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| CN105085679B (zh) * | 2014-04-25 | 2019-01-11 | 上海津曼特生物科技有限公司 | 全人源抗rankl抗体 |
| EP3012271A1 (en) | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| US10618976B2 (en) | 2015-06-16 | 2020-04-14 | The Board Of Trustees Of The Leland Stanford Junior University | SIRP-α agonist antibody |
| DK4186927T3 (da) | 2015-10-21 | 2025-06-10 | Ose Immunotherapeutics | Fremgangsmåder og sammensætninger til at ændre makrofagers polarisering til pro-inflammatoriske celler til behandling af kræft |
| PH12018550160B1 (en) * | 2016-04-14 | 2024-07-03 | Ose Immunotherapeutics | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| CN110325549B (zh) | 2016-12-09 | 2024-03-08 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
| PT3443010T (pt) | 2017-02-17 | 2024-10-21 | Ose Immunotherapeutics | Novos anticorpos anti-sirpa e suas aplicações terapêuticas |
| JP7160833B2 (ja) * | 2017-04-13 | 2022-10-25 | サイロパ ビー．ブイ． | 抗ｓｉｒｐアルファ抗体 |
| PT3625259T (pt) | 2017-05-16 | 2024-07-04 | Synthon Biopharmaceuticals Bv | Anticorpos anti-sirpalfa |
| EP3658589B1 (en) | 2017-07-26 | 2023-09-27 | Forty Seven, Inc. | Anti-sirp-alpha antibodies and related methods |
| CN111511766B (zh) | 2017-10-13 | 2024-06-07 | Ose免疫疗法 | 修饰的抗SIRPa抗体及其应用 |
| BR112020017709A2 (pt) | 2018-03-13 | 2020-12-29 | Ose Immunotherapeutics | Anticorpo anti-sirpa humana, fragmento de ligação a antígeno do mesmo ou anticorpo modificado do mesmo, composição farmacêutica, uso de um polipeptídeo, métodos para preparar um anticorpo anti-sirpa humana v1, para aumentar a apresentação cruzada de um antígeno e para avaliar a probabilidade de eficácia de um tratamento, método in vitro ou ex vivo para avaliar a probabilidade de eficácia de um tratamento, e, combinação de compostos |
| WO2019183266A1 (en) | 2018-03-21 | 2019-09-26 | ALX Oncology Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
| CR20200566A (es) | 2018-05-25 | 2021-02-19 | Alector Llc | Anticuerpos anti-sirpa y metodos de utilización de los mismos |
| MX2020013068A (es) | 2018-07-10 | 2021-03-02 | Univ Kobe Nat Univ Corp | Anticuerpo anti proteína reguladora de señales alfa sirpalfana. |
| EP3833391A4 (en) | 2018-08-08 | 2022-08-10 | Orionis Biosciences, Inc. | ANTI-SIRP1ALPHA CHIMERIC PROTEINS AND USES THEREOF |
| SG11202102851XA (en) | 2018-09-27 | 2021-04-29 | Celgene Corp | SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF |
| BR112021009325A2 (pt) | 2018-11-14 | 2021-09-14 | Arch Oncology, Inc. | Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de ensaio de expressão de sirp¿ em células tumorais e/ou imunes; e; composição farmacêutica |
| CN113412279B (zh) | 2018-11-15 | 2024-09-24 | 拜奥迪斯私人有限公司 | 人源化抗SIRPα抗体 |
| US20220235144A1 (en) | 2019-03-04 | 2022-07-28 | Qilu Puget Sound Biotherapeutics Corporation | Anti-sirp-alpha antibodies |
| US20210347908A1 (en) | 2019-08-20 | 2021-11-11 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel anti-sirpa antibodies |
| CN111635458B (zh) | 2020-03-20 | 2026-02-17 | 健信生物科技(宁波)有限公司 | 靶向Sirpα的抗体或其抗原结合片段及其制备和应用 |
| CN112010979B (zh) | 2020-08-21 | 2022-05-10 | 博奥信生物技术（南京）有限公司 | 一种抗人SIRPα单克隆抗体及其用途 |
| CN111995682B (zh) | 2020-08-21 | 2022-05-10 | 博奥信生物技术（南京）有限公司 | 抗人SIRPα单克隆抗体及其用途 |
| CN112574310B (zh) | 2020-12-11 | 2023-05-05 | 浙江博锐生物制药有限公司 | 抗SIRPα抗体及其用途 |
-
2017
- 2017-04-14 PH PH1/2018/550160A patent/PH12018550160B1/en unknown
- 2017-04-14 US US16/093,062 patent/US11279766B2/en active Active
- 2017-04-14 HU HUE17718881A patent/HUE068840T2/hu unknown
- 2017-04-14 KR KR1020187032968A patent/KR102355240B1/ko active Active
- 2017-04-14 IL IL262251A patent/IL262251B2/en unknown
- 2017-04-14 MD MDE20190221T patent/MD3443010T2/ro unknown
- 2017-04-14 DK DK17718881.0T patent/DK3443010T3/da active
- 2017-04-14 LT LTEPPCT/EP2017/059071T patent/LT3443010T/lt unknown
- 2017-04-14 UA UAA201809487A patent/UA126658C2/uk unknown
- 2017-04-14 CN CN202310060526.8A patent/CN115785272A/zh active Pending
- 2017-04-14 MX MX2018012434A patent/MX2018012434A/es unknown
- 2017-04-14 HR HRP20241316TT patent/HRP20241316T1/hr unknown
- 2017-04-14 SI SI201731557T patent/SI3443010T1/sl unknown
- 2017-04-14 EP EP24190165.1A patent/EP4438626A3/en active Pending
- 2017-04-14 FI FIEP17718881.0T patent/FI3443010T3/fi active
- 2017-04-14 SM SM20240438T patent/SMT202400438T1/it unknown
- 2017-04-14 RS RS20241172A patent/RS66062B1/sr unknown
- 2017-04-14 ES ES17718881T patent/ES2990971T3/es active Active
- 2017-04-14 JP JP2018550322A patent/JP7491666B2/ja active Active
- 2017-04-14 PL PL17718881.0T patent/PL3443010T3/pl unknown
- 2017-04-14 MA MA44665A patent/MA44665B1/fr unknown
-
2018
- 2018-09-19 ZA ZA2018/06293A patent/ZA201806293B/en unknown
- 2018-10-11 CL CL2018002898A patent/CL2018002898A1/es unknown
- 2018-10-14 SA SA518400237A patent/SA518400237B1/ar unknown
-
2022
- 2022-02-25 US US17/681,219 patent/US12252546B2/en active Active
- 2022-07-14 JP JP2022112873A patent/JP7549626B2/ja active Active
-
2025
- 2025-03-11 US US19/076,531 patent/US20250215108A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11987635B2 (en) | Anti-4-1BB antibodies and methods of making and using thereof | |
| CN109843927B (zh) | 抗b7-h3抗体、其抗原结合片段及其医药用途 | |
| JP2019520034A5 (enExample) | ||
| CN116239698A (zh) | 双功能融合蛋白及其医药用途 | |
| CN116693686A (zh) | 抗b7-h4抗体、其抗原结合片段及其医药用途 | |
| CN102753195A (zh) | 用于增强抗肿瘤抗体疗法的方法 | |
| EP4317186A1 (en) | Nanobody targeting bcma and application thereof | |
| CN115785272A (zh) | 新型抗-SIRPa抗体及其治疗应用 | |
| CN112480259B (zh) | 抗tnfr2抗体及其用途 | |
| WO2022143552A1 (zh) | Pd-1结合分子及其应用 | |
| CN110461874B (zh) | 抗gitr抗体、其抗原结合片段及其医药用途 | |
| WO2022228183A1 (zh) | 抗siglec15抗体及其制备方法和用途 | |
| IL307336A (en) | Novel tnfr2 binding molecules | |
| CN109384845B (zh) | 一种cd40单克隆抗体、其制备方法及其应用 | |
| CN114685666A (zh) | 抗间皮素纳米抗体及其应用 | |
| JP2024522349A (ja) | Ｃ－ｘ－ｃモチーフケモカイン受容体６（ｃｘｃｒ６）結合分子及びその使用方法 | |
| EP4403571A1 (en) | Human epidermal growth factor receptor binding molecule and use thereof | |
| CN111763258A (zh) | 抗ox40抗体及其用途 | |
| CN118043358A (zh) | Ctla-4结合分子及其应用 | |
| RU2761638C1 (ru) | Антитела против лиганда программируемой смерти (pd-l1) и их применение | |
| CN116444672B (zh) | 人表皮生长因子3的抗体、其制备方法及其应用 | |
| CN115947855B (zh) | 抗cd24抗体的制备及其用途 | |
| JPH08509963A (ja) | ＩｇＧ▲下３▼抗体を含む組成物 | |
| TW202144425A (zh) | 特異性抗原結合分子，其製備方法及醫藥用途 | |
| US20260008861A9 (en) | Anti-4-1bb antibodies and methods of making and using thereof |